Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR

Status Recruiting

Clinical Trial Summary

This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis.

Clinical Trial Description

Methodology: This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis. Study Design: The clinical trial will be conducted over a 6-week treatment period. - Group A: Patients currently taking pyridostigmine and experiencing pyridostigmine-related gastrointestinal (GI) adverse events (AEs) within the past 7 days - Group B: Patients not currently taking pyridostigmine due to GI AEs or that had their dose reduced due to pyridostigmine related GI AEs Group A will be enrolled in the study and randomized to either the control (pyridostigmine+ placebo) or the test group (pyridostigmine + ondansetron) and treated for 6 weeks. Following enrolment, patients may (if needed) titrate up their pyridostigmine dose at the investigator's discretion each week to the highest dose deemed appropriate, tolerable and safe by the Investigator. Group B patients not currently taking pyridostigmine due to GI AEs will initiate pyridostigmine at a dose determined by the investigator based on the patient's history and may titrate as deemed tolerable and safe by Investigator during screening; patients on a reduced dose due to pyridostigmine related GI AEs may titrate pyridostigmine as deemed tolerable and safe by the investigator during screening. If patients in Group B experience GI AEs that fulfil enrolment criteria, along with all other inclusion/exclusion criteria, they will be enrolled into the study at that dose and randomized to either the control (pyridostigmine+ placebo) or the test group (pyridostigmine + ondansetron) and treated for 6 weeks. Following enrolment, patients may (if needed) titrate up their pyridostigmine dose at the investigator's discretion each week to the highest dose deemed appropriate, tolerable and safe by the Investigator. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04226170
Study type	Interventional
Source	DAS-MG, Inc
Contact	Martine Francis, BA
Phone	301-343-8894
Email	martine@mafinc.com
Status	Recruiting
Phase	Phase 2
Start date	April 8, 2021
Completion date	April 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05039190` - Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients	Phase 3
Recruiting	`NCT04561557` - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System	Early Phase 1
Completed	`NCT01727193` - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy	Phase 3
Completed	`NCT00285350` - Mycophenolate Mofetil in Myasthenia Gravis	Phase 3
Recruiting	`NCT05890833` - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed	`NCT05694234` - Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Not yet recruiting	`NCT05095103` - Immune Profiles in Myasthenia Gravis
Not yet recruiting	`NCT04965987` - Oxaloacetate in Myasthenia Gravis	Phase 1
Completed	`NCT02774239` - A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)	Phase 3
Terminated	`NCT02102594` - Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)	Phase 2
Completed	`NCT02066519` - Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis	N/A
Completed	`NCT02118805` - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Terminated	`NCT01828294` - Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis	Phase 1
Terminated	`NCT00727194` - Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis	Phase 2
Completed	`NCT04590716` - Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
Recruiting	`NCT04837625` - Study of Myasthenic Crisis in China
Not yet recruiting	`NCT01469858` - Perception and Multisensory Integration in Neurological Patients Using fMRI	N/A
Completed	`NCT05408702` - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Completed	`NCT03205306` - Myasthenia Gravis and Psyche

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms